Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
Trial details
- Registry ID
- NCT05322473
- Phase
- Phase 2
The FDA approved Adalimumab on 31 Dec 2002.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis SuppurativaNCT05322473 | MoonLake Immunotherapeutics AG | Phase 2 | Completed | 2023-05-09Actual |
| Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic ArthritisNCT05640245 | MoonLake Immunotherapeutics AG | Phase 2 | Completed | 2023-09-05Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2002-12-31Day | Adalimumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA125057", "applicant_as_listed_by_fda": "ABBVIE INC", "brand_names": ["HUMIRA"], "active_ingredients": ["ADALIMUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20021231", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |